Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Clinical trial NCT06577532 · RECRUITING

Trial details

NCT number: NCT06577532
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Pancreatic Neoplasms Other Solid Tumors

Start date: 2024-09-24
Primary completion: 2026-12-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.